Portfolio Holdings Detail for ISIN IE00BYXG2H39

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE

Holdings detail for NMRA

Show aggregate NMRA holdings

News associated with NMRA

Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Underweight” Rating by JPMorgan Chase & Co.

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) was downgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued on Tuesday, Marketbeat.com reports. Separately, Mizuho upped their price objective on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” […] - 2025-09-18 02:24:43

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd increased its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 969.7% in the 1st quarter, HoldingsChannel reports. The firm owned 233,597 shares of the company’s stock after buying an additional 211,759 shares during the quarter. XTX Topco Ltd’s holdings in Neumora Therapeutics were worth $234,000 at the end […] - 2025-08-13 04:26:45

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of “Hold” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) has been assigned a consensus rating of “Hold” from the nine analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. […] - 2025-07-28 05:56:58

Cerity Partners LLC Has $303,000 Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Cerity Partners LLC increased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 24.0% during the first quarter, Holdings Channel.com reports. The fund owned 302,505 shares of the company’s stock after buying an additional 58,597 shares during the period. Cerity Partners LLC’s holdings in Neumora Therapeutics were worth $303,000 at the end of […] - 2025-07-28 04:32:49

Contrasting Neumora Therapeutics (NASDAQ:NMRA) and Edesa Biotech (NASDAQ:EDSA)

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) and Edesa Biotech (NASDAQ:EDSA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation. Earnings & Valuation This table compares Neumora […] - 2025-07-24 05:12:57

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. trimmed its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 12.5% in the first quarter, HoldingsChannel.com reports. The fund owned 114,371 shares of the company’s stock after selling 16,273 shares during the quarter. Alps Advisors Inc.’s holdings in Neumora Therapeutics were worth $114,000 at the end of the most recent […] - 2025-07-18 04:50:53

Neumora Therapeutics (NASDAQ:NMRA) & CERo Therapeutics (NASDAQ:CERO) Head-To-Head Contrast

CERo Therapeutics (NASDAQ:CERO – Get Free Report) and Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Analyst Recommendations This is a summary of […] - 2025-06-17 02:50:53

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System increased its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 793.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,457 shares of the company’s stock after acquiring an additional 48,362 shares during […] - 2025-06-12 04:50:46

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Position Trimmed by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD decreased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 94.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 32,548 shares of the company’s stock after selling 592,930 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Neumora Therapeutics were worth $346,000 […] - 2025-05-15 04:47:00

Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Price Target at $9.29

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) has earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have issued a buy recommendation on the company. […] - 2025-04-15 02:28:59

EntryPoint Capital LLC Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

EntryPoint Capital LLC purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 12,762 shares of the company’s stock, valued at approximately $135,000. Several other institutional investors and hedge funds have also made changes to their positions […] - 2025-03-31 05:32:51

Head to Head Contrast: Neumora Therapeutics (NASDAQ:NMRA) vs. Cidara Therapeutics (NASDAQ:CDTX)

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) and Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends. Profitability This table compares Neumora Therapeutics and […] - 2025-03-12 04:41:21

William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform

William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market perform rating in a report released on Monday, Marketbeat Ratings reports. NMRA has been the subject of several other research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on […] - 2025-03-11 04:26:46

Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Hold” Rating by Stifel Nicolaus

Stifel Nicolaus downgraded shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a hold rating in a research report released on Friday, Marketbeat reports. The firm currently has $2.00 price objective on the stock, down from their prior price objective of $6.00. Several other equities research analysts also recently commented on […] - 2025-03-10 04:28:54

Neumora Therapeutics (NASDAQ:NMRA) Lowered to “Neutral” Rating by Guggenheim

Guggenheim lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a neutral rating in a research note released on Friday morning, Marketbeat.com reports. Other analysts have also issued research reports about the stock. HC Wainwright lowered their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set […] - 2025-03-10 04:28:52

Needham & Company LLC Reaffirms Buy Rating for Neumora Therapeutics (NASDAQ:NMRA)

Needham & Company LLC restated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock. A number of other brokerages have also issued reports on NMRA. HC Wainwright reiterated a “buy” rating and […] - 2025-03-05 06:48:56

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Ieq Capital LLC

Ieq Capital LLC lowered its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 50.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,853 shares of the company’s stock after selling 38,000 shares during the period. Ieq Capital LLC’s holdings […] - 2025-02-28 07:18:55

Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $16.50

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year […] - 2025-02-26 04:56:47

Critical Survey: Neumora Therapeutics (NASDAQ:NMRA) and Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Institutional and Insider Ownership 31.4% of Adaptimmune […] - 2025-02-17 06:56:57

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) NMRA holdings

Share Trades of NMRA by Blackrock for IE00BYXG2H39

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-06	BUY	933	1.890	1.900	1.899	USD 1,772	1.34
2025-10-03	BUY	2,170	1.830	1.930	1.920	USD 4,166	1.34
2025-10-02	BUY	310	1.780	1.845	1.839	USD 570	1.34
2025-09-30	BUY	620	1.820	1.830	1.829	USD 1,134	1.33
2025-09-26	BUY	620	1.740	1.765	1.762	USD 1,093	1.33
2025-09-25	BUY	620	1.700	1.809	1.798	USD 1,115	1.33
2025-09-24	BUY	1	1.830	1.960	1.947	USD 2	1.32
2025-09-18	BUY	309	1.570	1.570	1.570	USD 485	1.32
2025-09-17	BUY	930	1.450	1.585	1.572	USD 1,461	1.32
2025-09-11	SELL	-310	1.660	1.670	1.669	USD -517	1.32 Loss of -109 on sale
2025-09-10	BUY	620	1.630	1.700	1.693	USD 1,050	1.32
2025-09-05	SELL	-310	1.680	1.700	1.698	USD -526	1.31 Loss of -121 on sale
2025-08-29	SELL	-930	1.730	1.760	1.757	USD -1,634	1.30 Loss of -426 on sale
2025-08-27	BUY	620	1.760	1.795	1.791	USD 1,111	1.29
2025-08-26	SELL	-310	1.740	1.780	1.776	USD -551	1.29 Loss of -150 on sale
2025-08-25	BUY	310	1.630	1.670	1.666	USD 516	1.29
2025-08-20	SELL	-1,232	1.610	1.645	1.641	USD -2,022	1.28 Loss of -440 on sale
2025-08-18	BUY	614	1.640	1.679	1.675	USD 1,029	1.28
2025-08-08	SELL	-610	1.460	1.690	1.667	USD -1,017	1.27 Loss of -241 on sale
2025-08-05	BUY	304	1.660	1.720	1.714	USD 521	1.27
2025-08-04	SELL	-301	1.650	1.790	1.776	USD -535	1.26 Loss of -155 on sale
2025-08-01	SELL	-602	1.560	1.920	1.884	USD -1,134	1.26 Loss of -375 on sale
2025-07-30	BUY	15,800	2.080	2.220	2.206	USD 34,855	1.25
2025-07-18	SELL	-526	1.850	2.170	2.138	USD -1,125	1.20 Loss of -493 on sale
2025-07-14	SELL	-2,128	1.270	1.340	1.333	USD -2,837	1.19 Loss of -298 on sale
2025-07-07	BUY	798	0.895	0.933	0.929	USD 742	1.20
2025-07-02	BUY	14,520	0.782	0.835	0.830	USD 12,047	1.21
2025-06-25	BUY	528	0.808	0.833	0.831	USD 439	1.22
2025-06-11	BUY	528	0.922	1.050	1.037	USD 548	1.26
2025-06-10	BUY	526	1.020	1.145	1.132	USD 596	1.26
2025-06-04	SELL	-263	0.790	0.805	0.804	USD -211	1.27 Profit of 124 on sale
2025-04-23	BUY	263	0.711	0.805	0.796	USD 209	1.50
2025-04-10	SELL	-2,112	0.717	0.746	0.743	USD -1,569	1.61 Profit of 1,838 on sale
2025-04-08	SELL	-264	0.724	0.825	0.815	USD -215	1.64 Profit of 218 on sale
2025-04-07	SELL	-264	0.753	0.770	0.768	USD -203	1.65 Profit of 234 on sale
2025-04-04	SELL	-1,320	0.737	0.850	0.839	USD -1,107	1.67 Profit of 1,097 on sale
2025-04-01	BUY	1,056	0.913	1.010	1.000	USD 1,056	1.69
2025-03-31	SELL	-792	1.000	1.010	1.009	USD -799	1.71 Profit of 552 on sale
2025-03-14	SELL	-4,240	1.280	1.426	1.411	USD -5,984	1.83 Profit of 1,786 on sale
2025-03-07	SELL	-530	1.490	1.490	1.490	USD -790	1.88 Profit of 208 on sale
2025-03-04	SELL	-265	1.410	1.500	1.491	USD -395	1.91 Profit of 112 on sale
2025-02-25	BUY	530	1.660	1.705	1.701	USD 901	1.96
2025-02-19	SELL	-265	1.660	1.720	1.714	USD -454	2.00 Profit of 75 on sale
2025-02-13	BUY	795	1.690	1.710	1.708	USD 1,358	2.04
2025-02-12	BUY	265	1.700	1.730	1.727	USD 458	2.05
2025-02-11	BUY	1,056	1.670	1.770	1.760	USD 1,859	2.06
2025-01-17	BUY	1,056	2.050	2.190	2.176	USD 2,298	2.25
2025-01-16	BUY	1,056	2.170	2.240	2.233	USD 2,358	2.26
2025-01-10	SELL	-528	2.210	2.350	2.336	USD -1,233	2.24 Loss of -52 on sale
2025-01-08	SELL	-1,056	2.370	2.550	2.532	USD -2,674	1.97 Loss of -593 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NMRA

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy